<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00253955</url>
  </required_header>
  <id_info>
    <org_study_id>HR355_3035</org_study_id>
    <nct_id>NCT00253955</nct_id>
  </id_info>
  <brief_title>Study to Demonstrate the Clinical Efficacy of Levofloxacin in the Treatment of Pneumonia</brief_title>
  <official_title>An Open-Label, Multicenter, Multinational, Centrally Randomized, Two-Arm Parallel-Group Study to Demonstrate the Non-Inferiority in Clinical Efficacy of Levofloxacin 750mg od in Comparison With Piperacillin/Tazobactam 4g/500mg Every 8 Hours in the Treatment of Mild to Moderate Hospital-Acquired Pneumonia Adult Patients in Both General Wards and ICU (Intensive Care Unit)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
        -  The primary objective of the study is to demonstrate the non-inferiority in clinical&#xD;
           efficacy at the test of cure (TOC) visit planned 5-7 days after treatment completion of&#xD;
           levofloxacin 750 mg once daily (od) in comparison with piperacillin/tazobactam 4 g/500&#xD;
           mg every 8 hours in treating adult patients suffering from mild to moderate&#xD;
           hospital-acquired pneumonia.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      The secondary objectives of the study are:&#xD;
&#xD;
        -  To assess the bacteriological efficacy at the test of cure (TOC) visit&#xD;
&#xD;
        -  To assess the clinical and bacteriological efficacy at the end of study (EOS) visit, 28&#xD;
           to 32 days after treatment ends&#xD;
&#xD;
        -  To assess the tolerability of both drugs&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical efficacy data:-Infection related signs and symptoms-Chest X-ray</measure>
    <time_frame>from the start to the end of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety data: Clinical adverse event reporting, including SAE reporting</measure>
    <time_frame>From the inform consent signed until the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteriological efficacy data:-Cultures and susceptibility testing</measure>
    <time_frame>from the start to the end of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">460</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin/Tazobactam</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects meeting all of the following criteria will be considered for enrollment into the&#xD;
        study:&#xD;
&#xD;
          -  General ward or ICU hospitalized subject.&#xD;
&#xD;
          -  Subject with diagnosis of hospital-acquired pneumonia of presumed bacterial origin&#xD;
             based upon:&#xD;
&#xD;
               -  Infection developing after at least 72 hours following hospital admission and&#xD;
&#xD;
               -  At least three of the four following signs:&#xD;
&#xD;
                    -  Fever, defined as body temperature (oral or tympanic temperature ≥ 38°C or&#xD;
                       rectal temperature ≥ 38.5°C)&#xD;
&#xD;
                    -  Purulent tracheal sputum production/secretion or change in sputum character&#xD;
&#xD;
                    -  Total peripheral white blood cell (WBC) count &gt; 12 G/L or &lt; 4.5 G/L or 15%&#xD;
                       immature neutrophils (bands), regardless of total peripheral WBC count&#xD;
&#xD;
                    -  Increased plasma or serum C reactive protein (CRP) level as shown by a level&#xD;
                       of at least twice the upper boundary of the hospital normal range and&#xD;
&#xD;
                    -  Chest X-ray findings (anterior posterior [AP] or posterior anterior [PA], if&#xD;
                       possible lateral view) in agreement with the clinical diagnosis of bacterial&#xD;
                       pneumonia, i.e. appearance of new, progressive pulmonary infiltrate(s)&#xD;
                       attributable to infectious etiology.&#xD;
&#xD;
          -  Subjects are required to have specimens collected for microbiological documentation&#xD;
             within 24 hours prior to enrolment. Specimens should include at least one invasive or&#xD;
             noninvasive lower respiratory tract specimen for Gram stain, culture and&#xD;
             susceptibility testing, and at least 2 venous blood samples for culture and&#xD;
             susceptibility testing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects presenting with any of the following will not be included in the study:&#xD;
&#xD;
        Related to the hospital-acquired pneumonia (HAP):&#xD;
&#xD;
          -  Suspected viral or fungal pneumonia, or HAP strongly suspected to be caused by MRSA&#xD;
             (methicillin-resistant Staphylococcus aureus) or organisms responsible for atypical&#xD;
             pneumonia, such as Chlamydia pneumoniae, Legionella pneumophila or Mycoplasma&#xD;
             pneumoniae&#xD;
&#xD;
          -  Patients with severe HAP, defined as presence of at least one of the following:&#xD;
&#xD;
               -  In previously non-ventilated patients: need for mechanical ventilation&#xD;
                  consequently to HAP&#xD;
&#xD;
               -  In previously ventilated patients: oxygenation rate defined by partial pressure&#xD;
                  of oxygen in arterial blood (PaO2)/fraction of inspired oxygen (FiO2) &lt; 200&#xD;
&#xD;
          -  Radiographic findings compatible with severe HAP, i.e. showing either:&#xD;
&#xD;
               -  Rapid progression (e.g. increase in the size of the opacity by ≥ 50% within 48&#xD;
                  hours of the current evaluation)&#xD;
&#xD;
               -  OR multilobar pneumonia (&gt; 2 lobes) or involvement of both lungs&#xD;
&#xD;
               -  OR cavitation of a lung infiltrate&#xD;
&#xD;
          -  Evidence of severe sepsis with hypotension and/or end-organ dysfunction, i.e.:&#xD;
&#xD;
               -  Shock commonly evidenced by: systolic blood pressure &lt; 90 mmHg or diastolic blood&#xD;
                  pressure &lt; 60 mmHg&#xD;
&#xD;
               -  In absence of previous vasopressors use, vasopressors use (except for fluid&#xD;
                  replacement) for more than 4 hours&#xD;
&#xD;
               -  In presence of vasopressors use, increase in vasopressors use (except for fluid&#xD;
                  replacement) for more than 4 hours&#xD;
&#xD;
               -  OR marked reduction in urine output (unless another explanation is available),&#xD;
                  i.e. in 1 hour: &lt; 20 mL or in 4 hours: &lt; 80 mL&#xD;
&#xD;
               -  OR acute renal failure requiring dialysis&#xD;
&#xD;
               -  OR profound alteration of mental status, i.e. marked lethargy/stupor/coma&#xD;
&#xD;
        Related to medical history/concomitant conditions:&#xD;
&#xD;
          -  Patients with any concomitant pulmonary diseases, conditions or complications that&#xD;
             could confound the interpretation or evaluation of drug efficacy or safety, including&#xD;
             severe bronchiectases, cystic fibrosis, active pulmonary tuberculosis or acute&#xD;
             pulmonary embolism, empyema, lung abscess or extra pulmonary extension of the LRTI&#xD;
             (lower respiratory tract infection), such as meningitis, septic arthritis,&#xD;
             endocarditis, known bronchial obstruction due to tumor or foreign body or with a&#xD;
             history of post-obstructive pneumonia (this does not exclude patients with COPD&#xD;
             [chronic obstructive pulmonary disease]), primary lung cancer or another malignancy&#xD;
             metastatic to the lungs, and/or requiring chemotherapeutic treatment (for this or&#xD;
             other reasons)&#xD;
&#xD;
          -  Patients with any known or suspected bacterial infection other than the disease under&#xD;
             investigation which will require concomitant use of a systemic antimicrobial agent&#xD;
             other than the study drug allocated&#xD;
&#xD;
          -  Patients who have received previous systemic antibiotics longer than 24 hours within&#xD;
             72 hours prior to the enrolment for the same episode of HAP&#xD;
&#xD;
          -  Body weight &gt; 95 kg&#xD;
&#xD;
          -  Patients with impaired renal function, as shown by creatinine clearance &lt; 20 mL/min&#xD;
&#xD;
          -  Hepatic cirrhosis with Child-Pugh score &gt; or = B&#xD;
&#xD;
          -  Immuno-compromised patients, such as those presenting with either:&#xD;
&#xD;
               -  Known HIV infection with a CD4 + T-lymphocyte count &lt; 0.2 G/L (i.e. &lt; 200&#xD;
                  cells/mm3)&#xD;
&#xD;
               -  Neutropenia - neutrophil count &lt; 1.0 G/I (i.e. &lt; 1000/mm3)&#xD;
&#xD;
               -  Patients on maintenance (≥ 3 months) corticosteroid therapy (&gt; 20 mg/day&#xD;
                  equivalent prednisolone)&#xD;
&#xD;
        Related to study drugs:&#xD;
&#xD;
          -  Patients with a microbiologically documented infection with a pathogen known prior to&#xD;
             inclusion to be resistant to at least one of the study medications&#xD;
&#xD;
          -  Patients with known or suspected hypersensitivity to, or known or suspected serious&#xD;
             adverse reaction to levofloxacin and/or piperacillin/tazobactam and/or any other&#xD;
             quinolones, beta-lactamase inhibitors, penicillins and/or to cephalosporins&#xD;
&#xD;
          -  Patients with epilepsy or a history of epilepsy or with predisposition to seizures&#xD;
             (e.g. patients with pre-existing central nervous system lesions)&#xD;
&#xD;
          -  Patients with known or suspected history of tendon disorders unless a potential&#xD;
             relationship to fluoroquinolone administration has been excluded.&#xD;
&#xD;
          -  Patients with latent or actual known defects in glucose-6-phosphate dehydrogenase&#xD;
             activity&#xD;
&#xD;
        General:&#xD;
&#xD;
          -  Women who are breast-feeding, or are failing to use adequate contraception; for&#xD;
             example, systemic hormones (birth control pills, implant), intrauterine device or&#xD;
             barrier method (diaphragm with intravaginal spermicide, cervical cap, male or female&#xD;
             condom), or are pregnant, as demonstrated by urine or serum pregnancy tests carried&#xD;
             out before exposure to study medication or the start of any study procedure that could&#xD;
             pose a risk to the foetus&#xD;
&#xD;
          -  Patients with a recent (within three months prior to study entry) history of drug or&#xD;
             alcohol abuse&#xD;
&#xD;
          -  Patients who have received any investigational drug within one month prior to study&#xD;
             entry.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Perdriset</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Caracas</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>Italy</country>
    <country>Lebanon</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Venezuela</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
  </removed_countries>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>November 14, 2005</study_first_submitted>
  <study_first_submitted_qc>November 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <last_update_submitted>November 7, 2008</last_update_submitted>
  <last_update_submitted_qc>November 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, Tazobactam Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

